These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 22672770)

  • 1. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
    Farlow M; Arnold SE; van Dyck CH; Aisen PS; Snider BJ; Porsteinsson AP; Friedrich S; Dean RA; Gonzales C; Sethuraman G; DeMattos RB; Mohs R; Paul SM; Siemers ER
    Alzheimers Dement; 2012 Jul; 8(4):261-71. PubMed ID: 22672770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease.
    Honig LS; Vellas B; Woodward M; Boada M; Bullock R; Borrie M; Hager K; Andreasen N; Scarpini E; Liu-Seifert H; Case M; Dean RA; Hake A; Sundell K; Poole Hoffmann V; Carlson C; Khanna R; Mintun M; DeMattos R; Selzler KJ; Siemers E
    N Engl J Med; 2018 Jan; 378(4):321-330. PubMed ID: 29365294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.
    Doody RS; Thomas RG; Farlow M; Iwatsubo T; Vellas B; Joffe S; Kieburtz K; Raman R; Sun X; Aisen PS; Siemers E; Liu-Seifert H; Mohs R; ;
    N Engl J Med; 2014 Jan; 370(4):311-21. PubMed ID: 24450890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
    Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
    Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.
    Siemers ER; Friedrich S; Dean RA; Gonzales CR; Farlow MR; Paul SM; Demattos RB
    Clin Neuropharmacol; 2010; 33(2):67-73. PubMed ID: 20375655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.
    Boada M; Anaya F; Ortiz P; Olazarán J; Shua-Haim JR; Obisesan TO; Hernández I; Muñoz J; Buendia M; Alegret M; Lafuente A; Tárraga L; Núñez L; Torres M; Grifols JR; Ferrer I; Lopez OL; Páez A
    J Alzheimers Dis; 2017; 56(1):129-143. PubMed ID: 27911295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease.
    Blennow K; Zetterberg H; Rinne JO; Salloway S; Wei J; Black R; Grundman M; Liu E;
    Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease.
    Galasko D; Farlow MR; Lucey BP; Honig LS; Elbert D; Bateman R; Momper J; Thomas RG; Rissman RA; Pa J; Aslanyan V; Balasubramanian A; West T; Maccecchini M; Feldman HH
    Alzheimers Res Ther; 2024 Jul; 16(1):151. PubMed ID: 38970127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
    Schneider LS; Kennedy RE; Cutter GR;
    Alzheimers Dement; 2010 Sep; 6(5):367-77. PubMed ID: 20813339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.
    Aisen PS; Saumier D; Briand R; Laurin J; Gervais F; Tremblay P; Garceau D
    Neurology; 2006 Nov; 67(10):1757-63. PubMed ID: 17082468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.
    Andreasen N; Simeoni M; Ostlund H; Lisjo PI; Fladby T; Loercher AE; Byrne GJ; Murray F; Scott-Stevens PT; Wallin A; Zhang YY; Bronge LH; Zetterberg H; Nordberg AK; Yeo AJ; Khan SA; Hilpert J; Mistry PC
    PLoS One; 2015; 10(3):e0098153. PubMed ID: 25789616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study.
    Timmers M; Streffer JR; Russu A; Tominaga Y; Shimizu H; Shiraishi A; Tatikola K; Smekens P; Börjesson-Hanson A; Andreasen N; Matias-Guiu J; Baquero M; Boada M; Tesseur I; Tritsmans L; Van Nueten L; Engelborghs S
    Alzheimers Res Ther; 2018 Aug; 10(1):85. PubMed ID: 30134967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab.
    Lachno DR; Evert BA; Vanderstichele H; Robertson M; Demattos RB; Konrad RJ; Talbot JA; Racke MM; Dean RA
    J Alzheimers Dis; 2013; 34(4):897-910. PubMed ID: 23302661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.
    Landen JW; Zhao Q; Cohen S; Borrie M; Woodward M; Billing CB; Bales K; Alvey C; McCush F; Yang J; Kupiec JW; Bednar MM
    Clin Neuropharmacol; 2013; 36(1):14-23. PubMed ID: 23334070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
    Carlson C; Estergard W; Oh J; Suhy J; Jack CR; Siemers E; Barakos J
    Alzheimers Dement; 2011 Jul; 7(4):396-401. PubMed ID: 21784350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.